Fortive Earnings Call Highlights Growth, Margins And Cash

Fortive ((FTV)) has held its Q1 earnings call. Read on for the main highlights of the call.

Fortive’s latest earnings call struck an upbeat tone, as management highlighted strong first‑quarter growth, expanding margins, and robust cash generation while acknowledging pockets of near‑term pressure. Executives emphasized momentum at core franchises like Fluke and recurring software businesses, and reaffirmed full‑year guidance despite tariff costs, calendar distortions, and cautious hospital spending.

Consolidated Revenue Growth

Fortive reported nearly $1.1 billion in Q1 revenue, up about 8% on a reported basis and just over 5% on a core basis, showing healthy top‑line momentum. Management noted that roughly 150 basis points of that core growth came from extra selling days, signaling that part of the strength reflects timing rather than a broad acceleration in demand.

Strong Profitability and Margin Expansion

Profitability moved ahead of revenue, with adjusted EBITDA rising about 13% to $314 million and margin expanding around 140 basis points to just above 29%. The company credited mix, productivity, and pricing for the improvement, reinforcing confidence that the Fortive Accelerator efficiency program is delivering sustainable margin gains.

Material EPS Growth

Earnings power continued to scale faster than sales, as adjusted EPS climbed more than 25% to $0.70, marking the third straight quarter of double‑digit expansion. Management framed this as proof that the portfolio’s higher‑margin, recurring and software components are increasingly driving the bottom line.

Free Cash Flow and Conversion

Cash generation remained a standout, with $194 million of free cash flow in Q1 and trailing 12‑month conversion running above 100%. That level of cash efficiency gives Fortive flexibility to fund investment, acquisitions, and returns to shareholders without stretching the balance sheet.

Share Repurchase Program

Fortive remained aggressive on buybacks, deploying about $500 million in Q1 alone and roughly $1.8 billion since the spin, retiring around 35 million shares. The company has reduced its diluted share count by just over 10% since mid‑2025, a meaningful tailwind for EPS even as it nudges leverage slightly higher.

Segment Performance — Intelligent Operating Solutions

The Intelligent Operating Solutions segment delivered about 8% reported and 5% core revenue growth, with adjusted EBITDA rising around 8% to $255 million. Despite tariff headwinds, IOS held an impressive roughly 65% gross margin and an adjusted EBITDA margin just above 34%, underscoring the unit’s strong competitive positioning.

Segment Performance — Advanced Healthcare Solutions

Advanced Healthcare Solutions posted $326 million of revenue, up about 8% year over year and roughly 6% on a core basis, even as U.S. hospitals stayed cautious on big capital outlays. Adjusted EBITDA jumped roughly 18% to $84 million, lifting segment margin by about 200 basis points to just under 26%, aided by mix and cost discipline.

Recurring Revenue and Software Strength

Recurring revenue grew faster than the company as a whole in both major segments, strengthening the visibility of future cash flows. Management highlighted double‑digit services growth at Fluke and robust software gains, including AI‑enabled launches such as Provation’s Mirror Documentation Assist, which are designed to deepen customer stickiness.

Product and Commercial Momentum

New products are gaining traction, with tools like CertiFiber Max driving pull‑through at Fluke and pushing orders ahead of revenue, keeping book‑to‑bill above one. Fortive also cited promising early results from “made‑in‑region” strategies in India and China, which support growth while helping to manage geopolitical and supply‑chain risks.

Capital Allocation and M&A Readiness

Management reiterated a disciplined capital allocation framework that prioritizes organic growth, bolt‑on acquisitions, share repurchases, and a modest but growing dividend. Two smaller recent deals are integrating on plan, and the corporate development team has been reinforced, suggesting the company is ready to pursue further targeted M&A when valuations and fit align.

Tariff‑Related Gross Margin Pressure

Not everything moved in Fortive’s favor, as consolidated adjusted gross margin slipped about 100 basis points to just over 63%, largely due to tariffs. IOS felt the brunt with roughly 150 basis points of compression, and management expects these tariff headwinds to linger through at least part of the third quarter before easing in the final months of the year.

Selling Days Distortion to Q1 Results

The company cautioned that Q1’s strength was flattered by calendar effects, with extra selling days adding roughly 150 basis points to core revenue growth overall. IOS saw about a 100‑basis‑point boost and AHS roughly 300 basis points, meaning investors should be careful not to over‑extrapolate the quarter’s growth rates into the rest of the year.

Hospital Capital Spending Headwinds

Within healthcare, Fortive continues to navigate a constrained U.S. hospital spending backdrop, which is weighing on discretionary capital purchases across parts of the AHS portfolio. Management did see modest sequential improvement but is still planning the business cautiously until capital budgets normalize more broadly.

Back Half Year Phasing and Q4 Headwind

Earnings phasing will get tougher later in the year, with Q4 facing a revenue headwind of $15 million to $20 million from four fewer selling days compared with last year. As cost savings from earlier actions are fully lapped and comparisons tighten, the company expects less margin expansion in the back half than in the first half.

Leverage and Short‑Term Funding

Fortive ended the quarter with gross debt at about 2.8 times adjusted EBITDA after using some commercial paper to help fund its substantial buyback activity. Management described the increase in leverage as modest and manageable, arguing that strong cash flow and earnings growth leave ample room for continued shareholder returns and selective M&A.

Tariff and Cost Timing Uncertainty

While price increases more than offset cost inflation in Q1 and are expected to remain favorable, the exact timing of tariff offsets and cost action benefits adds near‑term modeling noise. Investors should expect some quarterly volatility in gross and operating margins as these measures phase in and prior cost programs roll off.

Forward‑Looking Guidance and Outlook

Fortive reaffirmed full‑year 2026 adjusted EPS guidance of $2.90 to $3.00, now tracking toward the upper end, on 2% to 3% core revenue growth and about $4.3 billion of reported sales. Management sees Q2 and Q3 EPS roughly in line with Q1’s $0.70, flags a Q4 revenue drag from fewer selling days, and continues to target steady annual EBITDA margin expansion, backed by strong cash generation and disciplined capital deployment.

Fortive’s earnings call painted the picture of a company executing well on its strategy, using operational discipline and a richer mix of recurring and software revenue to grow earnings faster than sales. While tariffs, calendar shifts, and hospital budget caution pose near‑term challenges, management’s reaffirmed guidance, ongoing buybacks, and M&A readiness underscore confidence in the multiyear growth and margin story.